News

- CIMERLI is the first and only FDA-approved biosimilar interchangeable with Lucentis ®  (ranibizumab injection) for all indications, with 12 months of interchangeability exclusivity - - Interchangeability designation and clinical equivalence to Lucentis provides confidence that existing Lucentis

REDWOOD CITY, Calif. , Sept. 12, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences , Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will participate at the H.C. Wainwright 24 th Annual Global Investment Conference on Wednesday, September 14 at 10:00 am ET .

REDWOOD CITY, Calif. , Aug. 29, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective August 24, 2022 , the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 234,000 shares

– Commercial launch of CIMERLI ™ planned for early October 2022 – – PDUFA date for toripalimab BLA is December 23, 2022 – – Commercial preparation underway for planned July 2023 launch of YUSIMRY ™ – – UDENYCA® delivers 2 nd quarter 2022 net sales of $60.1 million – – Conference call today at 5

- CIMERLI™ is Coherus’ third FDA-approved product and the first of four new product launches planned by the end of 2023 - - First CIMERLI™ product sales expected in October 2022 - - COLUMBUS AMD trial was published in the journal Ophthalmology and demonstrated the clinical equivalence of CIMERLI™

REDWOOD CITY, Calif. , Aug. 01, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective August 1, 2022 , the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 250,000 shares of

REDWOOD CITY, Calif. , July 28, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences , Inc. (“Coherus”, Nasdaq: CHRS), today announced that its second quarter 2022 financial results will be released after market close on Thursday, August 4 th , 2022. Starting at 5 p.m.

-   FDA has set a target action date of December 23, 2022 for the toripalimab BLA - - Toripalimab will be the first and only immuno-oncology agent for NPC in U.S., if approved - REDWOOD CITY, Calif. , and SHANGHAI, China , July 06, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences , Inc. (“Coherus”,

REDWOOD CITY, Calif. , June 22, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective June 16, 2022 , the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 409,000 shares of

- Dr. O’Donnell-Tormey is a cancer immunology key opinion leader with more than 30 years leading the Cancer Research Institute’s efforts to advance cancer immunotherapies - REDWOOD CITY, Calif. , May 11, 2022 (GLOBE NEWSWIRE) -- Coherus Biosciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced

REDWOOD CITY, Calif. , May 10, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences , Inc. (“Coherus”, Nasdaq: CHRS), announced today that senior management will present at the following investor conferences in May. BofA Securities 2022 Healthcare Conference on Thursday, May 12 at 3:00 p.m.

– CIMERLI ™ BLA review progressing toward August 2022 action date – – Toripalimab BLA resubmission expected by mid-summer – – UDENYCA® delivers 1 st quarter 2022 net sales of $60.1 million – – 2022 R&D and SG&A expense guidance reduced by $20 million – – Conference call today at 4:30 p.m.

- Biotechnology Chief Financial Officer and highly regarded former healthcare investment banker brings decades of industry experience to Coherus’ immuno-oncology strategy execution - REDWOOD CITY, Calif. , May 05, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc.

REDWOOD CITY, Calif. , May 03, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective April 27, 2022 , the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 240,000 shares of

- The CRL requests a quality process change Coherus and Junshi believe is readily addressable - -   BLA resubmission anticipated by mid-summer 2022 with expected six month FDA review timeline - - Onsite inspections in China , impeded to date by COVID-19-related travel restrictions, are required for

REDWOOD CITY, Calif. , April 29, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Coherus BioSciences, Inc. (Nasdaq: CHRS), please note in the Conference Call Information, the start time should be 4:30 p.m. ET , not 5 p.m. ET as previously stated.

REDWOOD CITY, Calif. , and SHANGHAI, China , April 14, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences , Inc. (“Coherus”, Nasdaq: CHRS) and Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) announced today that the United States Food and Drug Administration ("FDA")

- Toripalimab plus chemotherapy provided superior progression free survival, overall survival, overall response rate and duration of response compared to chemotherapy alone - SHANGHAI, China , and REDWOOD CITY, Calif. , April 08, 2022 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co.

REDWOOD CITY, Calif. , April 05, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective March 31, 2022 , the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 461,000 shares

— Multiple near-term anticipated product launches and development of innovative immuno-oncology pipeline position Coherus for long-term growth – — Introducing 2026 revenue target of $1.2 billion in annual net sales from Coherus'  diversified product portfolio – REDWOOD CITY, Calif.

REDWOOD CITY, Calif. , March 22, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences , Inc. (“Coherus”, Nasdaq: CHRS), today announced that Coherus plans to host an Analyst Day on March 29, 2022 at 9:30 a.m. ET in New York City . Coherus executives and scientists will provide updates on the preparation

- Dr. Dias is a biotech and pharma industry executive with more than 20 years of global experience launching oncology products - REDWOOD CITY, Calif. , March 15, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: “CHRS”, “the Company”, “Coherus”) today announced Rosh Dias , MD, MRCP, has

– Toripalimab plus chemotherapy met both primary endpoint of progression free survival and prespecified secondary endpoint of overall survival compared to chemotherapy alone   – - Data support the use of toripalimab with chemotherapy as first-line treatment for advanced NSCLC patients without

REDWOOD CITY, Calif. , March 04, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences , Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the following investor conferences in March. 42 nd Annual Cowen Health Care Conference on Wednesday, March 9 at 10:30 a.m.

- Toripalimab plus chemotherapy demonstrates improvement in co-primary endpoints of PFS and OS in patients with advanced ESCC - - PFS and OS benefits were observed across all PD-L1 expression subgroups, including in patients with  low PD-L1 expression - REDWOOD CITY, Calif.

– YUSIMRY ™ (adalimumab-aqvh), Coherus’ second product, approved by FDA on December 17, 2021 – – BLAs under FDA review for PD-1 inhibitor toripalimab and CIMERLI ™ (ranibizumab-ranq) – – New FDA filings expected in 2022 for UDENYCA ® on-body injector and additional toripalimab indications – –

REDWOOD CITY, Calif. , Feb. 15, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: “CHRS”, “the Company”, “Coherus”) today announced Paul Reider has been named Chief Commercial Officer. Mr. Reider previously held the position of Executive Vice President of Commercial Operations and Market

REDWOOD CITY, Calif. , Feb. 14, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective Feb. 9, 2022 , the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 236,500 shares of

REDWOOD CITY, Calif. , Feb. 11, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences , Inc. (“Coherus”, Nasdaq: CHRS), today announced that its fourth quarter and full year 2021 financial results will be released after market close on Thursday, February 17, 2022. Starting at 5 p.m.

Jim Healy, Director since 2014, steps down from the Coherus board REDWOOD CITY, Calif. , Feb. 07, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences , Inc. (“Coherus” or the “Company”, Nasdaq: CHRS) today announced the appointment of board-certified oncologist and seasoned healthcare executive Lee N.

•  Coherus and Junshi Biosciences plan to evaluate the toripalimab + JS006 combination in clinical trials in multiple tumor types •  Combinations of PD-1 + TIGIT inhibitors have potential to expand checkpoint inhibitor utilization to new tumors and lines of therapy REDWOOD CITY, Calif.

Balance sheet strengthened to support commercial launches of as many as five new products in 2022 and 2023 REDWOOD CITY, Calif. , Jan. 07, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus or the Company) (Nasdaq: CHRS) today announced that it has entered into a loan agreement

REDWOOD CITY, Calif. , Jan. 04, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the virtual 40 th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 9 a.m. EST / 6 a.m. PST .